Monday, August 8, 2011

August - National Immunization Awareness Month

Our patients often come to us with questions about our stance on immunizations. The answer is that immunization choices are best made by the parents and what they believe are the best for their children. Our job are health care providers is to educate our patients so that they can make an informed decisions on what is best for their children.

To learn more about immunizations we invite you all to attend a free informational discussion hosted by Dr. Jesika DiCampli on Wednesday, August 24th 6pm at NFC.

In this edition of the NFC Newsletter:

Dr. DiCampli discusses possible adverse reactions to vaccines

Dr. Phranq Tamburri writes on the latest and cutting edge testing for prostate cancer risk assessment

And. . .

A Good Bye and Tribute to Dr. Konrad Kail by Dr. Shahrzad Orona
A pioneer and giant in the world of natural medicine, Dr. Konrad Kail died July 18, 2011, after a two and a half year battle with brain cancer.

To his patients, Dr. Kail was an invaluable asset. His combination of research and care combined with his background in conventional medicine and his innovation in natural remedies. Among his chief contributions were the NEAT allergy protocol and thyroflex device, which simplified and advanced treatment of often overlooked imbalances.

To his colleagues, Dr. Kail was a leader. Beginning his practice in the 1980s, when natural medicine was on the fringe of treatment in Arizona, Dr. Kail boldly established a clinic where eventually dozens of doctors would heal patients and hundreds of students would learn
his practices and discoveries.

Unlike many, Dr. Kail was unafraid to share medical knowledge and generously volunteered his findings and methods. On the myriad natural health boards he served, Dr. Kail patiently earned respect to accompany the fondness he engendered in fellow doctors.

And to his faith in natural medicine, Dr. Kail remained steadfast. He treated himself with conventional and natural methods, prolonging and enriching his last years to spend them with his beloved wife, Petie, with whom he built his medical legacy and beautiful life.

Could your child have an Allergic reaction to the aluminum in vaccines? by Dr. Jesika DiCampli

According to the European Journal of Pediatrics, there were cases of persistent pruritic nodules (intensely itchy lumps) at injection site reported after the use of several Aluminum adsorbed vaccines (DT/aP/polio+Hib) during vaccine trials in the 1990s (645 cases/76,000 recipients). Of these reactions, 77% were associated with aluminum allergy. Some children were skin tested for aluminum and all had positive reactions indicating delayed hypersensitivity to Aluminum. The median time between vaccination and onset of symptoms was 1 month, and symptoms can persist for up to 7 years.

The condition is important to recognize, as the child may suffer considerably. Future vaccinations with Aluminum containing vaccines may cause aggravation of the symptoms/allergy. Even though the incidence of itching nodules and aluminum allergy after administration of certain vaccines is probably low, research to replace aluminum containing vaccines seems appropriate.

Do you know the Arizona state vaccine requirements?

Come to Dr. DiCampli’s Talk on Vaccines to become more informed….

Latest News in Prostate Cancer Risk Assessment by Dr. Phranq Tamburri

A new non-invasive test has been reported for the early detection and current staging of prostate cancer. It is a urine test called testing for genetic molecular by-products TMPRSS2: ERG and PCA3. Now, despite the cumbersome title, this test is really an enhancement of a fairly modern but obscure prostate cancer test that Longevity Medical Health Center has pioneered since 2007. The test referred to is the PCA3 test; this is the second part of the new test mentioned above. You see, the PCA3 urine test has been used in Europe for years as an advanced screening tool that had been found much superior to a simple PSA screen. Recent research has found the PCA3 molecular urine test to be between 65-75% accurate in predicting cancer of the prostate. In the challenge of determining true prostate cancer risk, these are welcome odds. However, they could still be improved. This is the exciting news reported last week in the journal “Science Translational Medicine”. As stated earlier the discovery is not only a new ‘brother’ to the PCA3 called the ERG urine test but a new use for integrating both tests. Since each test is related to subtle differences in prostate cancer risk, the real excitement in this discovery was that linking these 2 tests together could greatly potentate the cancer risk assessment. Unfortunately the ERG test is not yet available although the rare PCA3 test is. Longevity Medical Health Center and Prostate Second Opinions can perform the PCA3 test while giving our patients the first opportunity for the dual urine test once it is released. Please contact our staff or Dr. Tamburri for more information on receiving the PCA3 test.